Caplin Point Laboratories is currently trading at Rs. 344.00, up by 3.35 points or 0.98% from its previous closing of Rs. 340.65 on the BSE.
The scrip opened at Rs. 340.00 and has touched a high and low of Rs. 352.30 and Rs. 340.00 respectively. So far 9474 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 456.00 on 14-Aug-2019 and a 52 week low of Rs. 180.00 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 355.95 and Rs. 307.00 respectively. The current market cap of the company is Rs. 2610.05 crore.
The promoters holding in the company stood at 69.03%, while Institutions and Non-Institutions held 4.47% and 26.50% respectively.
Caplin Point Laboratories’ wholly owned subsidiary company — Caplin Steriles has entered into a private label distribution agreement with Xellia Pharmaceuticals for five generic injectable ANDAs in the US. The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
